Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Promisia HealthcareNZSE:PHL -3.79%29 Debt-to-EBITDA is 4.17 as of Mar. 2026, which is 34% above its 10-year median of 3.12. GuruFocus rates NZSE:PHL with a GF Score™ of 29/100 and a GF Value™ of NZ$0.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 479 Healthcare Providers & Services companies, Promisia Healthcare ranks worse than 84.34% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Promisia Healthcare's Debt-to-EBITDA or its related term are showing as below:
NZSE:PHL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.7 Med: 3.12 Max: 21.6
Current: 7.22
During the past 13 years, the highest Debt-to-EBITDA Ratio of Promisia Healthcare was 21.60. The lowest was -2.70. And the median was 3.12.
NZSE:PHL's Debt-to-EBITDA is ranked worse than 84.34% of 479
companies
in the Healthcare Providers & Services industry
Industry Median: 2.18
vs NZSE:PHL: 7.22
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Promisia Healthcare Debt-to-EBITDA Related Terms
Promisia Healthcare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Promisia Healthcare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:PHL vs HCA, THC, EHC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Promisia Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Promisia Healthcare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Promisia Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Promisia Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Promisia Healthcare (NZSE:PHL) has a Debt-to-EBITDA of 4.17 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Promisia Healthcare. This is 34% above median its historical median of 3.12. According to the industry distribution chart, Promisia Healthcare ranks #404 out of 479 companies in the Healthcare Providers & Services industry, placing it in the top 84.3%.
Is Promisia Healthcare's Debt-to-EBITDA too high?
Promisia Healthcare's current Debt-to-EBITDA of 4.17 is 34% above median its 10-year median of 3.12. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.18. Promisia Healthcare's value of 4.17 is 91.3% above this industry median. Based on the distribution chart, Promisia Healthcare ranks #404 out of 479 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Promisia Healthcare has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Promisia Healthcare's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Promisia Healthcare ranks #404 out of 479 companies for Debt-to-EBITDA. This places Promisia Healthcare in the lower half of its industry. The industry median Debt-to-EBITDA is 2.18. Promisia Healthcare's value of 4.17 is 91.3% above this benchmark. While the company's 10-year median is 3.12 vs. the industry median of 2.18, Promisia Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.18, based on 479 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Promisia Healthcare's current Debt-to-EBITDA of 4.17 is 91.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Promisia Healthcare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Promisia Healthcare's current Debt-to-EBITDA is 4.17, which is 34% above median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promisia Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Promisia Healthcare (NZSE:PHL) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$0.43, compared to a current price of NZ$0.64 — trading 47.7% above its estimated fair value. The current Debt-to-EBITDA is 4.17, which is 34% above median its 10-year median of 3.12 and 91.3% above the Healthcare Providers & Services industry median of 2.18. Promisia Healthcare's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Promisia Healthcare (NZSE:PHL), the current Debt-to-EBITDA is 4.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Promisia Healthcare (NZSE:PHL) Overvalued in 2026?
Based on GuruFocus' analysis, Promisia Healthcare stock appears to be overvalued.
The current stock price of NZ$0.64 is trading 47.7% above its estimated GF Value™ of NZ$0.43.
GuruFocus considers Promisia Healthcare to be Significantly Overvalued.
Key valuation signals for NZSE:PHL:
Debt-to-EBITDA: 4.17 (34% above median its 10-year median of 3.12)
GF Value™: NZ$0.43 vs. price of NZ$0.64 (47.7% above fair value)
Industry Position: 91.3% above the Healthcare Providers & Services median (#404 of 479)
No single metric tells the full story. See the NZSE:PHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Promisia Healthcare Ltd is engaged in the provision of aged care in New Zealand. The company's services include Resthome Care, Hospital (Continuing) Care, Respite (Short Term) Care, Young Disabled Care, Dementia Care, and others. The Group operates in one operating segment: the provision of aged care in New Zealand.
29GF Score
Get the complete analysis for NZSE:PHL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:PHL has been successfully added to your 
